- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07436767
Segurança e Eficácia da Injeção de Células KL003 na Anemia Falciforme Grave
It is a single-arm, single-center, open-label, single-dose study. A total of three subjects with severe sickle cell disease (SCD), aged 12-50 years (inclusive), are planned to receive cell infusion. After successful hematopoietic stem cell engraftment is achieved in the first subject, cell infusion will be initiated for subsequent subjects.
Visão geral do estudo
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 301617
- Regenerative Medicine Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 12-50 years of age (inclusive) at the time of screening
- Diagnosed with sickle cell disease (SCD) with a βS/βS, βS/β0 or βS/β+ genotype.
- Experienced at least 4 severe vaso-occlusive events (VOEs) in the two years before informed consent, despite supportive care measures (e.g., a pain management plan).
- Have a Karnofsky Performance Status (KPS) score (for subjects ≥16 years) or Lansky Performance Status (LPS) score (for subjects <16 years) of ≥60.
- Have experienced either hydroxyurea (HU) failure at any time in the past or demonstrated intolerance to HU.
- Subject must have been treated and followed for at least two years before informed consent at the medical center that maintained detailed records of their sickle cell disease history.
- Be willing and able to comply with all study procedures and visit schedules.
- The subject and/or their legally authorized representative must voluntarily agree to participate, sign the informed consent form, and be capable of completing all follow-up assessments required by the protocol.
Exclusion Criteria:
- Have any severe active infection (fungal, bacterial, viral, tuberculosis, or other), including active Hepatitis B (defined as serum HBV-DNA ≥2000 IU/mL), active Hepatitis C virus (HCV) infection, positive human immunodeficiency virus (HIV) antibody, or active syphilis.
- Inadequate bone marrow function, as defined by an absolute neutrophil count of <1.0 x 10^9/L (<0.5 x 10^9/L for subjects on hydroxyurea treatment) or a platelet count <100 x 10^9/L.
- Have severe cerebrovascular disease, including a history of significant ischemic or hemorrhagic stroke, abnormal Transcranial Doppler (TCD) flow velocities requiring chronic transfusion therapy (>200 cm/s), occlusion or stenosis of the circle of Willis, or any history of moyamoya disease.
- Baseline oxygen saturation < 90% without supplemental oxygen (excluding periods of SCD crisis, severe anemia or infection).
- Baseline carbon monoxide diffusing capacity (DLCO) < 50% (corrected for Hb) in the absence of infection. If DLCO cannot be assessed due to age or cognitive limitations, there must be a normal respiratory exam, a chest radiograph without pulmonary infiltrates, and oxygen saturation by pulse oximetry ≥ 90% on room air.
- Baseline left ventricular ejection fraction (LVEF) < 45%
- Clinically significant pulmonary hypertension at baseline, as defined by the requirement for ongoing pharmacologic treatment or the consistent or intermittent use of supplemental oxygen.
- Baseline estimated glomerular filtration rate (eGFR) <70 mL/min/1.73 m^2
- Advanced liver disease
- Have a definite contraindication to stem cell collection.
- Have any prior or current malignancy, myeloproliferative disorder, or immunodeficiency disease.
- Have white blood count <3.0 x 10^9/L and/or platelet count <100.0 x 10^9/L not due to hypersplenism.
- Have a diagnosis of compound alpha-thalassemia (excluding silent carrier).
- Have significant iron overload at screening, defined as severe iron overload on liver MRI, or serum ferritin levels >2000 ng/mL, or cardiac T2* <10 ms.
- Have positive irregular red cell antibodies or platelet antibodies.
- Be eligible for allogeneic hematopoietic stem cell transplantation and have an identified willing, fully HLA-matched donor.
- Prior receipt of gene therapy or allogeneic hematopoietic stem cell transplantation.
- Immediate family member with a known or suspected Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome, and familial adenomatous polyposis).
- Have a diagnosed major psychiatric disorder or predisposition that, in the Investigator's opinion, would severely compromise the ability to participate in the clinical study.
- Have an uncorrectable coagulation disorder or a history of severe hemorrhagic disease.
- Have any other condition that, in the opinion of the treating physician, renders the subject unsuitable for hematopoietic stem cell transplantation.
- Have a known allergy to the investigational drug(s) (e.g., plerixafor, busulfan) or their components.
- Have participated in or are currently participating in another interventional clinical study within 3 months before screening.
- Received a live vaccine within 6 weeks before screening.
- Be pregnant or breastfeeding.
- The subject or their partner is unwilling to use medically acceptable effective contraception during the 32-month study period.
- Unable to receive red blood cell transfusion.
- The subject or their parent/guardian is unable to adhere to the study protocol.
- Have any other condition deemed by the Investigator to make the subject unsuitable for participation in this study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental
A single intravenous infusion of ≥ 3.0 × 10^6 CD34+ cells/kg was administered. |
KL003 is an autologous CD34⁺ hematopoietic stem cell gene therapy product in which the βA-T87Q-globin gene is transduced via a lentiviral vector. Through genetic modification, the patient's autologous CD34⁺ hematopoietic stem cells are engineered to differentiate into red blood cells expressing functional β-globin, thereby increasing overall hemoglobin levels, improving anemia, and ultimately eliminating transfusion dependence. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The proportion of subjects who achieve successful engraftment of CD34⁺ cells modified with the βA-T87Q-globin lentiviral vector
Prazo: From Day 0 to Day 42 after cell infusion
|
Achieving neutrophil engraftment, defined as an absolute neutrophil count ≥ 0.5 × 10^9/L for three consecutive days. |
From Day 0 to Day 42 after cell infusion
|
|
Incidence and severity of adverse events
Prazo: Adverse events will be monitored from baseline through study completion, up to 24 months.
|
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event |
Adverse events will be monitored from baseline through study completion, up to 24 months.
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CP-KL003-006/02
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .